-
Indonesian rescuers find debris from missing plane
-
Wembanyama scores 39 as Spurs overcome Edwards, Wolves in thriller
-
Heartbreak for Allen as Broncos beat Bills in playoff thriller
-
British qualifier upsets 20th seed Cobolli in Melbourne
-
Paolini races into round two to kickstart Australian Open
-
Portugal presidential vote wide open as far-right surge expected
-
Lutz kicks Broncos to overtime thriller as Bills, Allen fall short
-
Marchand closes Austin Pro Swim with 200m breaststroke win
-
Raducanu says Australian Open schedule 'does not make sense'
-
Australia great Martyn says he was given '50/50 chance' of survival
-
Top-ranked Alcaraz, Sabalenka headline Australian Open day one
-
Haiti security forces commence major anti-gang operation
-
NFL's Giants ink John Harbaugh as new head coach
-
Skipper Martinez fires Inter six points clear, injury-hit Napoli battle on
-
NASA moves moon rocket to launch pad ahead of Artemis 2 mission
-
Silver reveals PSG talks over NBA Europe plan
-
Iran leader demands crackdown on 'seditionists' after protests
-
Carrick magic dents Man City Premier League bid as Arsenal held
-
Kane scores as Bayern deliver comeback romp over Leipzig
-
Arteta angry as Arsenal denied penalty in Forest stalemate
-
Glasner feels 'abandoned' by Palace hierarchy
-
Israel objects to line-up of Trump panel for post-war Gaza
-
Dupont guides Toulouse to Champions Cup last 16 after Sale hammering
-
Arsenal extend Premier League lead despite drawing blank at Forest
-
Kane scores in Bayern comeback romp over Leipzig
-
Skipper Martinez fires Inter six points clear, Napoli squeeze past Sassuolo
-
Lookman gives Nigeria third place after AFCON shoot-out with Egypt
-
Thousands march in France to back Iranian protesters
-
Egadze glides to European figure skating gold
-
Lens hold off Auxerre to retake top spot from PSG
-
Trump threatens Europe with tariffs over Greenland as protesters rally
-
EU, Mercosur bloc ink major trade deal, reject 'tariffs' and 'isolation'
-
Feinberg-Mngomezulu captains Stormers into Champions Cup last 16
-
Hundreds in London protest against Beijing 'mega embassy'
-
Man Utd hurt City title hopes as Spurs flop again
-
Last-gasp Can penalty gives Dortmund win against St Pauli
-
Greenland protesters tell Trump to keep US hands off Arctic island
-
Skipper Martinez fires Inter past Udinese and six points clear
-
Carrick urges consistency from 'fantastic' Man Utd after derby win
-
Man City well beaten by 'better' Man Utd, concedes Guardiola
-
Real Madrid overcome Bernabeu boos to record Arbeloa's first win
-
Trump invites more leaders to join Gaza 'Board of Peace'
-
Man Utd dominate Man City in dream start for Carrick
-
CAF boss backs Kenya, Tanzania and Uganda to hold successful AFCON in 2027
-
Swiss ace Odermatt romps to Wengen downhill win
-
Museveni: Uganda's ex-revolutionary entering 5th decade in power
-
'We can hunt': Greenlanders weigh drastic options as US threatens
-
Uganda's Museveni wins seventh term as observers denounce intimidation
-
Former ECB chief Mario Dragi wins Charlemagne Prize
-
Iran's leader demands crackdown on 'seditionists' after protests
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
A.Kunz--VB